Basics |
CRISPR Therapeutics AG
CRISPR Therapeutics AG is a gene editing company. It is engaged in the development of CRISPR/Cas9-based therapeutics.
|
IPO Date: |
October 19, 2016 |
Sector: |
Healthcare |
Industry: |
Biotech |
Market Cap: |
$4.55B |
Activated in VL: |
True |
Average Daily Range |
Avg Daily Range: |
$1.62 | 2.80%
|
Avg Daily Range (30 D): |
$1.45 | 2.79%
|
Avg Daily Range (90 D): |
$1.17 | 2.80%
|
Institutional Daily Volume |
Avg Daily Volume: |
1.14M |
Avg Daily Volume (30 D): |
3.29M |
Avg Daily Volume (90 D): |
2.4M |
Trade Size |
Avg Trade Size (Sh.): |
64 |
Avg Trade Size (Sh.) (30 D): |
63 |
Avg Trade Size (Sh.) (90 D): |
63 |
Institutional Trades |
Total Inst.Trades: |
5,519 |
Avg Inst. Trade: |
$2.81M |
Avg Inst. Trade (30 D): |
$4.96M |
Avg Inst. Trade (90 D): |
$3.66M |
Avg Inst. Trade Volume: |
.04M |
Avg Inst. Trades (Per Day): |
3 |
Market Closing Trades |
Avg Closing Trade: |
$5.16M |
Avg Closing Trade (30 D): |
$20.06M |
Avg Closing Trade (90 D): |
$10.14M |
Avg Closing Volume: |
80.03K |
|
|
Financials |
|
TTM |
Q4 2024 |
FY 2024 |
Basic EPS
|
$-1.58
|
$-.42
|
$-4.34
|
Diluted EPS
|
$-1.58
|
$-.42
|
$-4.34
|
Revenue
|
$ .87M
|
$ 35.69M
|
$ 37.31M
|
Gross Profit
|
$
|
$
|
$
|
Net Income / Loss
|
$ -136M
|
$ -37.31M
|
$ -366.25M
|
Operating Income / Loss
|
$ -148.42M
|
$ -64.59M
|
$ -466.57M
|
Cost of Revenue
|
$
|
$
|
$
|
Net Cash Flow
|
$ -63.11M
|
$ 72.67M
|
$ -91.27M
|
PE Ratio
|
|
|
|
|
|
|